Pacific Bio (PACB) Reports In-Line Q4 EPS

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $36.96 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
• The First Of Long Island (FLIC) Misses Q1 EPS by 3c